Laurence H. Klotz

Canadian Journal of Urology, Vol.10, No.3, pp. 1819-1820, 2003

Abstract This article has no abstract. More >

Sean R. Downing^1,2, Pamela J. Russell^1,2, Paul Jackson^1,2

Canadian Journal of Urology, Vol.10, No.4, pp. 1924-1933, 2003

Abstract Introduction: Mutations in the p53 tumor suppressor gene are generally believed to be a late event in the progression of prostate cancer, and are associated with androgen-independence, increased angiogenesis, metastasis, recurrence, and a worse prognosis. In this review, we examine the current literature available on p53 mutations found in prostate cancer and focus on stages A (T1) and B (T2) of the disease. The alteration of genes involved in p53 regulation are also examined, as well as animal models that support an early role for p53 in the initiation and development of prostate cancer.
Results: We report… More >

Annette M. Walsh¹, Gregory G. Bailly², David G. Bell², Richard W. Norman², Rekha Gupta¹, Ekram Zayed¹, Bassam A. Nassar^1,3,*

Canadian Journal of Urology, Vol.10, No.5, pp. 2000-2006, 2003

Abstract Objectives: Urothelial carcinomas have a synchronous or metachronous multifocal pattern of occurrence, questioning their clonal origin. Genetic alterations such as microsatellite instability (MSI) affect various tumors including urothelial cancers. These alterations can affect repeat sequences and cause mutations in coding regions of genes involved in transformation, tumor suppression and apoptosis. Recently, the eight-guanine (G₈) and the seven-guanine (G₇) repeat sequences of the BAX and AXIN2 genes respectively, were shown altered in different cancers. Since BAX is involved in apoptosis while the AXIN2 is involved in β-catenin metabolism, a protein involved in cell adhesion and DNA transcription, and… More >

Armen G Aprikian¹, Neil Fleshner², Adrian Langleben³, Jeffrey Hames⁴

Canadian Journal of Urology, Vol.10, No.5, pp. 1986-1994, 2003

Abstract Objectives: To provide context in oncology for the significance of the benefits and cost of combined androgen blockade (CAB) in the treatment of advanced prostate cancer.
Methods: Canadian drug costs for the survival benefit with CAB in advanced prostate cancer were compared with the costs of benefit with new treatments in advanced non-small-cell lung cancer (NSCLC), metastatic colorectal cancer, and metastatic breast cancer. Clinical toxicities were also compared.
Results: The survival benefit with CAB in advanced prostate cancer appears to be approximately 3 months. The survival benefit with the addition of vinorelbine to cisplatin for the treatment of… More >

R. Choo¹, L. Sugar², E. Hong¹, K. Mackenzie¹, G. DeBoer¹, C. Danjoux¹, G. Morton¹, L. Klotz²

Canadian Journal of Urology, Vol.10, No.5, pp. 1981-1985, 2003

Abstract Objective: To evaluate whether there is any histologic progression from radical prostatectomy (RP) to local recurrence in patients with clinically isolated local recurrence following RP.
Methods and materials: A total of 43 patients with clinically isolated, biopsy proven, local recurrence following RP were retrospectively analyzed with respect to the change in Gleason score (GS) from RP to local recurrence. Central pathology review was undertaken for both RP and local recurrence biopsy specimens. The changes in primary and secondary Gleason grade (GG), and any potential correlation between the extent of GS change and other variables were also examined.
Results:… More >

Alexander Agranovich¹, Piotr Czaykowski², David Hui³, Tom Pickles⁴, Winkle Kwan¹

Canadian Journal of Urology, Vol.10, No.6, pp. 2056-2061, 2003

Abstract Objective: To review retrospectively the outcome and toxicity of Radiotherapy (RT) in the cohort of elderly patients (EP) with muscle-invasive urinary bladder carcinoma (MIUBC).
Methods: Thirty-six EP were treated with RT with radical intent. The age of the cohort ranged from 71 to 89 years with a median of 79 years. Eighty percent of the patients had Eastern Cooperative Oncology Group (ECOG) 0 and 1 performance status. Conventional and accelerated fractionation RT regimen were utilized.
Results: With median follow up of 45.8 months, the median survival was 23.9 months. There was a trend toward better survival in patients More >

Alan So, S. Larry Goldenberg, Martin E. Gleave

Canadian Journal of Urology, Vol.10, No.6, pp. 2040-2050, 2003

Abstract Since its discovery in 1979, serum PSA has revolutionized how physicians manage men with prostate cancer. PSA screening, although currently under much debate, has been recommended by most North American medical bodies, including the Canadian Urological Association, to be performed as a shared-decision making process after discussing with patients the pros and cons of treatment. Although most commonly thought of as a screening tool, serum PSA has also been used to predict tumor volume, stage and prognosis in patients before and after treatment. In this review, we examine PSA testing and its effectiveness in the More >

Malcolm J. Moore

Canadian Journal of Urology, Vol.10, No.6, pp. 2038-2039, 2003

Abstract The benefits of chemotherapy in men with symptomatic HRPC include pain relief, better physical functioning and improved quality of life. These have been well established in randomized trials. A meaningful or statistically significant improvement in survival has yet to be demonstrated. In the absence of a survival benefit, there is concern that treating men when they are free of symptoms may have a negative impact upon quality of life due to drug related toxicity. It will also limit or eliminate any therapeutic options when symptoms eventually develop and therapy is needed most. More >

Nancy A. Dawson

Canadian Journal of Urology, Vol.10, No.6, pp. 2036-2037, 2003

Abstract A multidisciplinary approach to prostate cancer has become the rule and not the exception. Involving the entire team, which includes a medical oncologist, from the time of initial diagnosis is optimal. This facilitates maximal patient education regarding treatment options and enhances informed decision making.
A coordinated approach also promotes enrollment on clinical trials, which are often, multimodality, especially in high-risk early stage prostate cancer. Integrated therapeutic strategies throughout the patient's disease course can improve both patient care and satisfaction. More >

Michael Pether, S. Larry Goldenberg, Kapil Bhagirath, Martin Gleave

Canadian Journal of Urology, Vol.10, No.2, pp. 1809-1814, 2003

Abstract Introduction: This report will review the long-term follow-up of a prospective Phase II evaluation of intermittent androgen suppression in the treatment of prostate cancer. Specifically, this analysis will address completed cycle characteristics, the concept of prolonged off-treatment cycles, the time to cancer progression, cancer-specific survival and the association between PSA and bone scan changes.
Methods: A total of 102 patients have been entered into this protocol. Treatment was initiated with combined androgen blockade and continued for 6 months or longer to reach a serum PSA nadir. Medication was then withheld until the serum PSA increased to predetermined… More >